Broncho-Vaxom通过改善鼻黏膜Th1/Th2细胞因子平衡缓解持续性变应性鼻炎
结果显示BV组药物评分及鼻部症状评分显著下降,鼻灌洗液IL-4、IL-13降低而IFN-γ升高,IL-4/IFN-γ比值降低,鼻涂片嗜酸性粒细胞减少,且疗效持续至治疗后4至8周。
要点
- BV可显著降低持续性变应性鼻炎患者的药物评分和鼻部症状评分。
- BV降低鼻灌洗液IL-4、IL-13并升高IFN-γ,改善Th1/Th2平衡。
- BV减少鼻涂片嗜酸性粒细胞,疗效至少持续至治疗后4至8周。
核心结论
- 口服Broncho-Vaxom可显著且持续缓解持续性变应性鼻炎症状,可能作为替代治疗策略。
- BV通过恢复和维持正常Th1/Th2细胞因子平衡改善整体黏膜免疫。
研究设计与样本
- 在基线、BV治疗结束时、治疗后4周和8周测量临床症状和过敏性炎症实验室指标。
主要发现
- BV组药物评分较安慰剂组显著下降,同时总鼻症状评分和个体鼻症状评分显著下降(瘙痒评分:23.72±5.32%;鼻漏评分:18.59±4.83%;喷嚏评分:23.08±4.98%)。
- BV组鼻灌洗液IL-4和IL-13水平显著降低,IFN-γ水平显著升高,IL-4/IFN-γ比值显著降低。
- BV治疗后鼻涂片嗜酸性粒细胞减少,BV诱导的有利变化至少持续至治疗后4至8周。
临床怎么用
- 对于持续性变应性鼻炎患者,可考虑口服BV作为替代治疗策略。
- BV通过改善鼻黏膜Th1/Th2细胞因子平衡发挥作用,疗效可持续至治疗后4至8周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Probiotics are mainly distributed in the mucosal system and have the ability to enhance mucosal barrier function and regulate immune responses. Broncho-Vaxom (BV), as a probiotic, has been applied to patients suffering from respiratory tract infections, but its potential effectiveness in allergic rhinitis (AR) has not been evaluated in human. This study aimed to investigate the clinical efficacy of BV in patients with persistent AR and to elucidate the underlying cellular mechanisms. METHODS: Sixty patients with AR were enrolled to this study and were randomly assigned to the BV group (n=30) and the placebo group (n=30). Changes of clinical symptoms and laboratory parameters of allergic inflammation were measured at baseline visit, immediately after BV treatment, four weeks, and eight weeks after the BV treatment. RESULTS: After BV treatment, medication score in the BV group was significantly decreased compared with placebo group, along with a significant drop of the total nasal symptom score and the individual nasal symptom scores (itching score: 23.72±5.32%; nasal rhinorrhea score: 18.59±4.83%; sneezing score: 23.08±4.98%). The levels of IL-4 and IL-13 in nasal lavage were diminished remarkably while the level of INF-γ was markedly increased in the BV group. This rendered a significant reduction of the ratio of IL-4/INF-γ. Moreover, a decrease of eosinophils in nasal smear was observed after BV treatment. The BV-induced favorable changes sustained for at least four to eight weeks post BV treatment. CONCLUSION: Oral administration of BV offers remarkable and sustained efficacy in alleviating AR symptoms and may be considered as an alternative therapeutic strategy for patients with persistent AR. BV acts by improving the overall mucosal immunity via restoring and maintaining the normal Th1/Th2 cytokine balance as an underlying cellular/signaling mechanism.
引用
- Meng Q, Li P, Li Y, et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa. Rhinology. 2019. PMID: 31403136. doi:10.4193/Rhin19.161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。